CG Oncology Inc. (CGON) Rallies on Strong Revenues
· Stocks · QuoteReporter
CG Oncology Inc. (CGON) Post Earning Analysis
CG Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative bladder-sparing therapies for bladder cancer patients. Founded in 2010 by Alex Yeung and Paul A. DeRidder and based in Irvine, California, the company’s lead product, cretostimogene, is currently in clinical development for treating Non-Muscle Invasive Bladder Cancer (NMIBC).
CG Oncology, Inc. (Ticker: CGON) recently disclosed its financial outcomes for the third quarter of 2025, revealing a loss for the period. However, the company managed to exceed revenue expectations, which could suggest a positive trajectory in terms of sales performance.
Additionally, on the same day, CG Oncology provided a broader update on its business operations. This update included more comprehensive insights into the company’s financial health and strategic initiatives moving forward.
The impact of these announcements on CGON’s stock could be mixed. On one hand, the reported loss might concern investors about the company’s profitability. On the other hand, surpassing revenue estimates could indicate growing market acceptance and sales expansion, potentially boosting investor confidence. Moreover, the business updates provided might have included forward-looking statements that could influence investor expectations positively, depending on the strategic directions and growth initiatives disclosed by the company.
The current price of the asset at $41.30, reflecting a significant daily increase of 8.45%, indicates a robust short-term upward momentum. This is underscored by its proximity to the week’s high of $41.50, showing a minimal gap of just -0.48%. However, the price is still 9.35% below the 52-week and year-to-date high of $45.56, suggesting there’s potential room for growth before encountering major resistance.
The moving averages provide a mixed but generally positive outlook. The asset is slightly below the 20-day moving average by -0.09%, indicating a potential consolidation or minor resistance around this level. However, it is well above the 50-day and 200-day moving averages by 4.42% and 41.52%, respectively, highlighting a strong medium to long-term uptrend.
The RSI at 53.34 is neutral, suggesting the asset is neither overbought nor oversold, providing no clear extremes in market sentiment. The MACD being slightly negative at -0.13 hints at a potential slowdown in the bullish momentum or a consolidation phase.
Overall, the asset shows a strong recovery from its 52-week low of $14.80, with a significant increase of 179.05% from both the 52-week and year-to-date lows. This robust upward trend over the longer term, coupled with the current price’s proximity to recent highs, suggests a cautiously optimistic outlook, with attention to be paid on whether it can breach and sustain above the short-term resistance marked by the 20-day moving average and the recent weekly high.
Price Chart
CG Oncology, Inc. (NASDAQ: CGON) reported its financial outcomes for the third quarter of 2025, ending September 30, with notable developments in its financial status and clinical advancements. The company’s cash reserves increased slightly to $680.3 million, up from $661.1 million in the previous quarter, bolstered by $48.7 million in net proceeds from equity sales, ensuring operational funding into the first half of 2028.
Significant financial metrics include a dramatic increase in R&D expenses to $27.9 million, up 42% year-over-year, primarily due to escalated clinical trial activities and expanded workforce. G&A expenses surged to $23.3 million, a 168% increase, largely driven by heightened legal and professional fees. This contributed to a net loss of $43.8 million, or ($0.57) per share, reflecting a 114% increase from the previous year’s $20.4 million, or ($0.30) per share.
Revenue showed a substantial rise to $1.666 million, a 3,770% increase from the prior year, led by gains in commercial and development sectors. On the regulatory front, CG Oncology initiated a rolling Biologics License Application (BLA) for its promising bladder cancer therapy, cretostimogene, with completion expected in 2026.
Clinical updates included positive results from ongoing trials and expedited enrollments, underscoring the company’s robust pipeline and potential for future growth. No dividends or share repurchases were announced.
Earnings Trend Table
| Date | Estimate EPS | Reported EPS | Surprise % | |
|---|---|---|---|---|
| 0 | 2025-11-11 | -0.57 | -0.57 | -0.00 |
| 1 | 2025-05-13 | -0.40 | -0.45 | -11.57 |
| 2 | 2025-03-28 | -0.35 | -0.48 | -35.85 |
| 3 | 2024-11-12 | -0.37 | -0.30 | 18.29 |
| 4 | 2024-08-08 | -0.37 | -0.28 | 24.73 |
| 5 | 2024-05-09 | -0.29 | -0.36 | -24.14 |
Over the last eight quarters, the earnings per share (EPS) trends for the company have shown significant fluctuations with both positive and negative surprises. The data reveals a pattern of inconsistency in meeting or exceeding analyst estimates.
Starting from the most recent quarter (Q4 2025), the company reported an EPS exactly in line with estimates at -0.57, indicating no surprise. This stability was not observed in the previous quarters. For instance, in Q2 2025, the company underperformed relative to expectations by 11.57%, reporting an EPS of -0.45 against an estimate of -0.40. An even larger negative surprise occurred in Q1 2025, where the reported EPS of -0.48 was significantly below the estimate of -0.35, resulting in a -35.85% surprise.
Conversely, in the latter half of 2024, the company demonstrated better-than-expected performance. In Q4 2024, it exceeded estimates by 18.29%, reporting an EPS of -0.30 against an estimate of -0.37. This trend of positive surprises continued into Q3 2024, with a reported EPS of -0.28 versus an estimate of -0.37, translating to a 24.73% positive surprise. However, Q2 2024 saw a deviation from this pattern, with a -24.14% surprise as the reported EPS of -0.36 fell short of the -0.29 estimate.
This analysis indicates a volatility in the company’s financial performance, with significant swings between underperformance and overperformance relative to analyst expectations. Such trends suggest potential challenges in forecasting and stability, which could be of concern to investors and stakeholders monitoring the company’s financial health.
The most recent rating changes for the stock in question reflect a generally optimistic outlook from various financial analysis firms.
- Guggenheim (October 8, 2025) – The latest rating comes from Guggenheim, which initiated coverage with a “Buy” status and a target price of $90. This rating suggests a strong bullish outlook on the stock, indicating Guggenheim’s confidence in the stock’s future performance and potential for significant price appreciation.
- Piper Sandler (August 19, 2025) – Shortly before Guggenheim, Piper Sandler also initiated coverage, albeit with a slightly more conservative “Overweight” rating and a target price of $55. While still optimistic, the target price set by Piper Sandler is considerably lower than that of Guggenheim, pointing to varying expectations about the stock’s growth prospects.
- Goldman Sachs (July 10, 2025) – Goldman Sachs resumed coverage on the stock with a “Buy” rating and a target price of $40. This action indicates a positive outlook, though the target price is the lowest among the recent ratings, suggesting a cautious optimism about the stock’s upward potential.
- JP Morgan (May 2, 2025) – Earlier in the year, JP Morgan initiated coverage with an “Overweight” rating and a target price of $41. This rating and target are closely aligned with Goldman Sachs’s view, indicating a general consensus on moderate growth expectations among major financial institutions.
Overall, these ratings illustrate a positive sentiment towards the stock across a spectrum of professional analysts, though with varying degrees of enthusiasm and target price expectations. The range in target prices from $40 to $90 also highlights differing views on the stock’s future market performance.
The current price of the stock is $41.30, which, when compared to the average target price set by various analysts, indicates potential for growth. Guggenheim’s target of $90 suggests a highly optimistic outlook, significantly above the current market price. Piper Sandler’s target of $55 and JP Morgan’s target of $41 also reflect positive sentiment, with Goldman’s target at $40 being closely aligned with the current price.
This range of target prices from respected analysts implies a general consensus on the stock’s potential to appreciate, particularly highlighted by the substantial upside seen in Guggenheim’s projection. The variation in target prices underscores differing views on the extent of growth or the factors influencing the stock’s future performance.
In summary, the stock exhibits a promising outlook as per analyst expectations, with most targets lying above the current market price, indicating a bullish sentiment on its future valuation.
Disclaimer: The information provided here is for educational and informational purposes only and should not be interpreted as financial advice, investment recommendations, or trading guidance. Markets involve risk, and past performance is not indicative of future results. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions. By acting, you accept full responsibility for your choices.